Anti-epileptic drug may soon join list of cheap medication from Canada
Individuals who suffer from uncontrollable epilepsy may benefit from a new medication that is one step closer to becoming accessible through Canadian pharmacies.
Individuals who suffer from uncontrollable epilepsy may benefit from a new medication that is one step closer to becoming accessible through Canadian pharmacies.
Last fall, Health Canada approved Vimpat for use to treat epileptic adults whose seizures are not being controlled through conventional therapy. In April, the Canadian Expert Drug Advisory Committee, a branch of the Common Drug Review (CDR), recommended that the drug be listed as an add-on therapy for patients who meet certain requirements.
The CDR's criteria suggests that patients must be under the care of a physician who is experienced in the treatment of epilepsy. In addition, individuals need to prove that other anti-epileptic drugs were ineffective in order to qualify for Vimpat.
Health experts are excited about the increasing popularity of Vimpat, which is the first new treatment for epilepsy that has been approved in nearly 10 years. Approximately 30 percent of people with epilepsy experience uncontrolled seizures, which highlights the need for new, affordable medication that helps these patients' improve their quality of life.
Many people who suffer from recurring health problems opt to purchase cheap medication from Canada. If provincial and territorial governments decide to fund Vimpat through their public drug benefit programs, consumers will likely receive ample savings on this product by shopping through a Canadian online pharmacy.
|
